Literature DB >> 10477517

KDR receptor: a key marker defining hematopoietic stem cells.

B L Ziegler1, M Valtieri, G A Porada, R De Maria, R Müller, B Masella, M Gabbianelli, I Casella, E Pelosi, T Bock, E D Zanjani, C Peschle.   

Abstract

Studies on pluripotent hematopoietic stem cells (HSCs) have been hindered by lack of a positive marker, comparable to the CD34 marker of hematopoietic progenitor cells (HPCs). In human postnatal hematopoietic tissues, 0.1 to 0.5% of CD34(+) cells expressed vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR). Pluripotent HSCs were restricted to the CD34+KDR+ cell fraction. Conversely, lineage-committed HPCs were in the CD34+KDR- subset. On the basis of limiting dilution analysis, the HSC frequency in the CD34+KDR+ fraction was 20 percent in bone marrow (BM) by mouse xenograft assay and 25 to 42 percent in BM, peripheral blood, and cord blood by 12-week long-term culture (LTC) assay. The latter values rose to 53 to 63 percent in LTC supplemented with VEGF and to greater than 95 percent for the cell subfraction resistant to growth factor starvation. Thus, KDR is a positive functional marker defining stem cells and distinguishing them from progenitors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477517     DOI: 10.1126/science.285.5433.1553

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  64 in total

1.  Circulating endothelial precursors: mystery, reality, and promise.

Authors:  S Rafii
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

2.  In silico cloning of novel endothelial-specific genes.

Authors:  L Huminiecki; R Bicknell
Journal:  Genome Res       Date:  2000-11       Impact factor: 9.043

Review 3.  Angiogenesis in hematologic malignancies and its clinical implications.

Authors:  Renchi Yang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

Review 4.  Peripheral blood stem cells: phenotypic diversity and potential clinical applications.

Authors:  Yichi Zhang; Bing Huang
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

Review 5.  VEGF as a mediator of tumor-associated immunodeficiency.

Authors:  J E Ohm; D P Carbone
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

6.  Differential increase of CD34, KDR/CD34, CD133/CD34 and CD117/CD34 positive cells in peripheral blood of patients with acute myocardial infarction.

Authors:  F Grundmann; C Scheid; D Braun; C Zobel; H Reuter; R H G Schwinger; J Müller-Ehmsen
Journal:  Clin Res Cardiol       Date:  2007-08-13       Impact factor: 5.460

7.  MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation.

Authors:  Nadia Felli; Laura Fontana; Elvira Pelosi; Rosanna Botta; Desirée Bonci; Francesco Facchiano; Francesca Liuzzi; Valentina Lulli; Ornella Morsilli; Simona Santoro; Mauro Valtieri; George Adrian Calin; Chang-Gong Liu; Antonio Sorrentino; Carlo M Croce; Cesare Peschle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

Review 8.  Hemangioblasts representing a functional endothelio-hematopoietic entity in ontogeny, postnatal life, and CML neovasculogenesis.

Authors:  Gregor Prindull
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

Review 9.  Hematopoietic stem cells.

Authors:  Robert G Hawley; Ali Ramezani; Teresa S Hawley
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

10.  Susceptibility loci for intracranial aneurysm in European and Japanese populations.

Authors:  Kaya Bilguvar; Katsuhito Yasuno; Mika Niemelä; Ynte M Ruigrok; Mikael von Und Zu Fraunberg; Cornelia M van Duijn; Leonard H van den Berg; Shrikant Mane; Christopher E Mason; Murim Choi; Emília Gaál; Yasar Bayri; Luis Kolb; Zulfikar Arlier; Sudhakar Ravuri; Antti Ronkainen; Atsushi Tajima; Aki Laakso; Akira Hata; Hidetoshi Kasuya; Timo Koivisto; Jaakko Rinne; Juha Ohman; Monique M B Breteler; Cisca Wijmenga; Matthew W State; Gabriel J E Rinkel; Juha Hernesniemi; Juha E Jääskeläinen; Aarno Palotie; Ituro Inoue; Richard P Lifton; Murat Günel
Journal:  Nat Genet       Date:  2008-11-09       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.